Aligos Therapeutics (ALGS) Current Assets (2019 - 2026)

Aligos Therapeutics has reported Current Assets for 8 years, with the latest figure at $59.6 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 58.36% year-over-year to $59.6 million; the trailing twelve-month figure through Mar 2026 stood at $59.6 million (down 58.36% YoY), and the FY2025 full-year result was $82.9 million, up 33.35% from the prior year.
• Current Assets for Q1 2026 stood at $59.6 million, down from $82.9 million in the prior quarter.
• The five-year high for Current Assets was $195.1 million in Q1 2022, with the low at $59.6 million in Q1 2026.
• Historically, Current Assets has averaged $114.3 million across 5 years, with a median of $109.4 million in 2023.
• Annual changes were most pronounced in 2025 — Current Assets jumped 33.35% — and 2026, when it slumped 58.36%.
• Aligos Therapeutics' Current Assets stood at $133.5 million in 2022, then climbed by 5.65% to $141.1 million in 2023, then slumped by 55.95% to $62.1 million in 2024, then surged by 33.35% to $82.9 million in 2025, then slipped by 28.04% to $59.6 million in 2026.
• The last three Current Assets figures came in at $59.6 million (Q1 2026), $82.9 million (Q4 2025), and $103.4 million (Q3 2025), per Business Quant data.